Meloxicam-d3 – 1 mg

Brand:
Cayman
CAS:
942047-63-4
Storage:
-20
UN-No:
De Minimis - 2811 / 6.1

Meloxicam-d3 is intended for use as an internal standard for the quantification of meloxicam (Item No. 14906) by GC- or LC-MS. Meloxicam is a selective inhibitor of COX-2 (IC50s = 11.8 and 143 μM for COX-2 and COX-1, respectively, in an enzyme activity assay) and a non-steroidal anti-inflammatory drug (NSAID).{5788} Meloxicam (0.03%) reduces croton oil-induced increases in TNF-α and IL-1β mRNA levels and increases IL-10 mRNA levels in cornea in a rabbit model of acute ocular inflammation.{15890} It inhibits pleural plasma exudation in a carrageenan-induced rat model of pleurisy when administered at a dose of 3 mg/kg.{5788} In a canine model of unilateral osteoarthritis of the right stifle joint, meloxicam reduces prostaglandin E2 (PGE2) levels in plasma and right stifle joint synovial fluid when administered at a dose of 0.2 mg/kg.{13042} Formulations containing meloxicam have been used in the treatment of osteoarthritis and rheumatoid arthritis.  

 

Available on backorder

SKU: 25508 - 1 mg Category:

Description

An internal standard for the quantification of meloxicam by GC- or LC-MS


Formal name: 4-hydroxy-2-(methyl-d3)-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxide

Synonyms: 

Molecular weight: 354.4

CAS: 942047-63-4

Purity: ≥99% deuterated forms (d1-d3)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Small Molecule Inhibitors|Cyclooxygenases||Research Area|Immunology & Inflammation|Arthritis (Non-autoimmune)||Research Area|Immunology & Inflammation|Autoimmunity|Rheumatoid Arthritis||Research Area|Immunology & Inflammation|Inflammatory Lipid Mediators|Prostaglandins||Research Area|Lipid Biochemistry|Cyclooxygenase Pathway||Research Area|Neuroscience|Ophthalmology||Research Area|Neuroscience|Pain Research